Urinary Retinol-Binding Protein as a Prognostic Marker in GlomerulopathiesMastroianni Kirsztajn G. · Nishida S.K. · Silva M.S. · Ajzen H. · Moura L.A. · Pereira A.B.
Division of Nephrology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Tubulointerstitial involvement seems to have a decisive influence on the progression of glomerular diseases. We have prospectively evaluated the levels of urinary retinol-binding protein (urRBP), a marker of proximal tubular dysfunction, in patients with different glomerulopathies (GPs) and correlated these levels with disease progression. By studying 238 patients with GPs, we found that urRBP tend to be lower in minimal change disease, glomerular hematuria and poststreptococcal glomerulonephritis as compared to focal segmental glomerulosclerosis, membranous nephropathy and membranoproliferative glomerulonephritis. By following 149 patients for up to 10 years, we have concluded that high levels of urRBP can identify patients who will progress with loss of renal function (defined as doubling of serum creatinine level) and that a urRBP level >1 mg/l was an efficient and independent indicator of poor prognosis as shown by multivariate analysis. This prediction was possible at a time when serum creatinine and creatinine clearance were still in the normal range. Our data suggest that this laboratory test adds important clinical information to the follow-up of GPs.
© 2002 S. Karger AG, Basel
- Böhle A, Mackensen-Haen S, von Gise H, Grund KE, Wehrmann M, Batz C, Bogenschütz O, Schmitt H, Nagy J, Müller C, Müller G: The consequences of tubulointerstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract 1990;186:135–144.
- Peterson PA, Berggard I: Isolation and properties of a human retinol-transporting protein. J Biol Chem 1971;246:25–33.
- Pereira AB, Nishida SK, Vieira JGH, Lombardi MTFC, Silva MS, Ajzen H, Ramos OL: Monoclonal antibody-based immunoenzymometric assays of retinol-binding protein. Clin Chem 1993;39:472–476.
- Bernard AM, Lauweris RR: Retinol-binding protein in urine: A more practical index than urinary β2-microglobulin for the routine screening of renal tubular function. Clin Chem 1981;27:1781–1782.
- Topping MD, Forster HW, Dolman C, Luczynska CM, Bernard AM: Measurement of urinary retinol-binding protein by enzyme-linked immunoassay, and its application to detection of tubular proteinuria. Clin Chem 1986;32:1863–1866.
- Beetham R, Dawnay A, Landon J, Cattell WR: A radioimmunoassay for retinol-binding protein in serum and urine. Clin Chem 1985;31:1364–1367.
Henry RJ, Sobel C, Segalove M: Turbidimetric determination of proteins with sulfosalicylic and trichloroacetic acids. Proc Soc Exp Biol Med 1956;92:748.
- Fairley KF, Birch DT: Hematuria: A simple method for identifying glomerular bleeding. Kidney Int 1982;21:105–108.
- Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, William DG: Adult-onset minimal change nephrotic syndrome: A long-term follow-up. Kidney Int 1986;29:1215–1223.
- Popovic-Rolovic M, Kostic M, Antic-Peco A, Jovanovic O, Popovic D: Medium- and long-term prognosis of patients with acute poststreptococcal glomerulonephritis. Nephron 1991;58:393–399.
Brenner BM, Rector FC: The Kidney, ed 3. Philadelphia, Saunders, 1986.
- Kolowski BW, Taylor ML, Baer MT, Blyler EM, Trahms C: Anticonvulsant medication use and circulating levels of total thyroxine, retinol-binding protein, and vitamin A in children with delayed cognitive development. Am J Clin Nutr 1987;46:360–368.
- Donaldson MDC, Chambers RE, Woolridge MW, Whicher JT: α1-Microglobulin, β2-microglobulin and retinol-binding protein in childhood febrile illness and renal disease. Pediatr Nephrol 1990;4:314–318.
- Beetham R, Dawnay A, Menabawy M, Silver A: Urinary excretion of albumin and retinol-binding protein during normal pregnancy. J Clin Pathol 1988;41:1089–1092.
- Portman RJ, Kissane JM, Robson AM: Use of β2-microglobulin to diagnose tubulointerstitial renal lesions in children. Kidney Int 1986;30:91–98.
- Wehrmann M, Böhle A, Held H, Schumm G, Kendziorra H, Pressler H: Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990;33:115–122.
- Mastroianni Kirsztajn G, Nishida SK, Silva MS, Ajzen H, Pereira AB: Urinary retinol-binding protein as a prognostic marker in the treatment of nephrotic syndrome. Nephron 2000;86:109–114.
Brenner BM, Coe FL, Rector FC: Clinical Nephrology. Philadelphia, Saunders, 1987.
McCrory WW: Glomerulonephritis: Pediatric aspects. Bull NY Acad Med 1970;46:789–796.
- Espinel CH, Gregory AW: Differential diagnosis of acute renal failure. Clin Nephrol 1980;13:73–77.
- Sesso R, Rettori R, Nishida S, Sato E, Ajzen H, Pereira AB: Assessment of lupus nephritis activity using urinary retinol-binding protein. Nephrol Dial Transplant 1994;9:367–371.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.